Can deep sleep or nerve stimulation flush toxic proteins from the brain?

NCT ID NCT06421532

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tests whether a sleep-deepening drug (lower-sodium oxybate) or a nerve-stimulating device (non-invasive vagus nerve stimulation), or both, can help clear amyloid-beta protein from the brain in people with cerebral amyloid angiopathy (CAA). Sixty participants will be randomly assigned to one of the treatments for three months. The main goal is to measure changes in amyloid levels in spinal fluid, with brain scans used to track disease progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
lower-sodium oxybate (XYWAV) and non-invasive vagus nerve stimulation (gammaCore Sapphire)
What this could lead to
If successful, this could point toward a new way to clear harmful protein buildup in the brain and slow disease progression in cerebral amyloid angiopathy.
What could go wrong
This is a small, early-phase trial (60 people) testing a biomarker, not a clinical outcome. The interventions may not improve symptoms or prevent bleeding, and side effects from the drug or device are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CEREBRAL AMYLOID ANGIOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Leiden University Medical Center (LUMC)

    Leiden, 2333ZA, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.